magic ocean book

magic ocean book

CHICAGO (AP) — N.J. Benson had 22 points and 17 rebounds in DePaul's 84-65 victory over Loyola Maryland on Saturday. Benson added 17 rebounds for the Blue Demons (9-4). Jacob Meyer added 12 points while shooting 4 for 11 (0 for 3 from 3-point range) and 4 of 4 from the free-throw line while they also had five rebounds. CJ Gunn went 4 of 11 from the field (1 for 5 from 3-point range) to finish with 11 points. The Greyhounds (5-6) were led in scoring by Jacob Theodosiou, who finished with 22 points. Milos Ilic added 13 points, six rebounds and two steals for Loyola (MD). Jordan Stiemke had 10 points. DePaul took the lead with 18:45 left in the first half and did not relinquish it. Benson led their team in scoring with 14 points in the first half to help put them up 44-26 at the break. DePaul extended its lead to 64-36 during the second half, fueled by an 8-0 scoring run. Isaiah Rivera scored a team-high 10 points in the second half as his team closed out the win. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .SEALSQ Announces Completion of a $25.0 Million Registered Direct Offering

Fever tickets 2025: Cheapest prices, seat map, full schedule for WNBA games in Indianapolis | Sporting NewsSpotswood's Hoover signs with Longwood

Harris dismisses ‘project fear’ approach to Sinn Fein

Haynes' 18 help George Mason defeat Mount St. Mary's 64-56None

OTTAWA — Peter Anholt tried to keep things light as he emerged from one of the elevators at Canada’s hotel. The temperature had been turned way up on the veteran hockey executive and the country’s under-20 program after a stunning upset some 12 hours earlier. “You only want to talk to me when things are bad, eh?” Anholt joked to reporters Saturday morning. “Is that how this works?” That is indeed what happens when a powerhouse with a record 20 gold medals expected to roll over an opponent suffers one of its worst all-time defeats at the tournament. Canada was embarrassed on home soil 3-2 by Latvia — a country it had thumped by a combined 41-4 score across four previous meetings — in a shocking shootout Friday. Coming off a disastrous fifth-place finish last year in Sweden and having talked a lot about upping their compete level and preparation, the Canadians looked disjointed for long stretches against the plucky, hard-working Latvians. The power play finally clicked late in the third period, but stands at 1-for-7 through two games, while the top line of Easton Cowan, Calum Ritchie and Bradly Nadeau has yet to translate its pre-tournament chemistry into success in the spotlight. “We’re certainly trying to problem solve, but not throw the baby out with the bath water,” said Anholt, who heads the world junior setup. “We’ve got to be really careful.” Canada, which picked up a solid 4-0 victory over Finland to open its tournament Thursday, had plenty of offensive zone time and directed 57 shots at Latvian goaltender Linards Feldbergs. Included in that total, however, were far too many one-and-done efforts from the perimeter with little traffic in front. There were, of course, desperate spurts — especially late in regulation and in 3-on-3 overtime — but not nearly enough for a roster peppered with first-round NHL draft picks and top prospects. “We played really, really hard,” Anholt said in defending his players. “We controlled the puck lots. We created some chances. Their goalie was really good and they defended really good ... 99 times out of 100 we win that game.” Hoping for a big response Sunday against Germany before meeting the United States on New Year’s Eve to tie a bow on round-robin action in Group A, Canada will have to push ahead minus one of its best players. Star defenceman Matthew Schaefer was injured Friday and is done for the tournament after he slammed into Latvia’s net and skated off favouring his left shoulder area. “Tough blow for the kid,” Anholt said. “The way he plays the game, he plays it at such a high speed.” Cowan, a Toronto Maple Leafs first-round selection, said Canada remains confident despite Friday’s ugly result in the nation’s capital. “We’re good,” said the 19-year-old from Mount Brydges, Ont. “Everyone’s lost a hockey game before.” But not like that — or to that opponent on that stage. “Bit of a (crappy) feeling,” said Nadeau, a Carolina Hurricanes prospect from St-Francois-de-Madawaska, N.B. “We all know what this group is capable of. Losing that game is not our standard. “We’ll bounce back.” Some corners of social media exploded following the Latvian debacle, with heavy criticism directed at head coach Dave Cameron and the team’s overall roster construction. “We’re not really worried about it,” defenceman and Ottawa native Oliver Book, who like Cowan is back from last year’s team, said of the outside noise. “We know we didn’t play well.” Canada appears poised to mix things up against the Germans. Vancouver Canucks prospect Sawyer Mynio of Kamloops, B.C., is set draw in for Schaefer, while Anholt indicated there’s a good chance forward Carson Rehkopf will get his first crack at the 2025 tournament as a returnee. The 19-year-old Seattle Kraken second-round pick from Vaughan, Ont., has scored a combined 78 goals over his last 97 regular-season and playoff games in the Ontario Hockey League. “Great player,” Cowan said. “He finds ways.” Anholt said taking a big-picture approach is key in challenging moments. “Let’s not panic,” he said. “The world hasn’t fallen in. It’s hard, but we’ll learn from it.” It’s something Canada will have to do under intense scrutiny. “People are gonna love you and people are gonna hate you,” said Cowan, who has a goal an assist through two games. “Gotta keep doing you.” Anholt, who was also at the helm 12 months ago when Canada never got in gear, isn’t getting 2024 vibes from this year’s group. “Not even in any way, shape or form,” he said. “We’ve just got to take care of business.” They get a first shot at redemption Sunday. This report by The Canadian Press was first published Dec. 28, 2024. Joshua Clipperton, The Canadian Press

None

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen

Lemonade's chief business officer Maya Prosor sells $1.5 million in stock

Trump Steps Into Skilled-Work Visa Clash, Saying They’re ‘Great’

KyKy Tandy, FAU close out Oklahoma State in CharlestonSocial media firms raise 'serious concerns' over Australian U-16 banNone